Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 / Phase 2 Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

Next Previous
Trial Profile

A Phase 1 / Phase 2 Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BMX 001 (Primary) ; Cisplatin
  • Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer
  • Focus Adverse reactions
  • Acronyms BMX-HN
  • Sponsors BioMimetix

    • Most Recent Events

    • 09 Jan 2023 The sequential assignment is added in the trial. The study Assessing safety of drug in which patients Experience Grade 4 or 5 also by escalating doses of BMX-001 and Each dose will be reported separately. The Incidence Radiation-induced Mucositis by Clinician Scoring is reduced from 12 months to 6 months, hence protocol was amendment.
    • 16 Nov 2022 Status changed from active, no longer recruiting to completed.
    • 26 Aug 2020 Planned End Date changed from 1 Feb 2020 to 1 Feb 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top